Ann: ONJCRI Evaluates Monepantel Anti-Cancer Mechanism, page-84

I think a lot of us are sceptical, and for good reason.

Ive now been on board for about 15 months, from 4-6¢.
I was sold on the science and immediacy of the dog cancer deal. It was said to be handed in by Xmas.
The ‘trial’ was pathetic.
It wasn’t even registered as such with the relevant authorities.
I gave them lee-way because we were told that the ‘trial’ was devised in conjunction with Elanco.
Then Covid happened: mTOR inhibitors were known to kill SARS-CoV-1 several years previously, and the research had been published in peer-review journals. The company lagged behind everyone else, and when they made progress, they didn’t promote it at all.
They sat on the verified report comparing MPL favourably to remdesivir for about 3 weeks... only announcing it the day that Elanco pulled-the-pin?!

We’ve got RA in the UK, RM between holidays and home, and RB doing god-knows-what out of his apartment at the Docklands. All the while, the Company Secretary is trying to drip feed the masses emailing him.

Then along comes MND.

And now the Olivia Newton John statement.

Do they really know what they want to do?
Do they really have any idea of where they which to focus their energies?

So, yes: there are several of us who are sceptical.
I control a T25 position: I want this to work.

Will it?